Net profit of Cohance Lifesciences declined 76.01% to Rs 36.72 crore in the quarter ended December 2025 as against Rs 153.07 crore during the previous quarter ended December 2024. Sales declined 19.47% to Rs 544.55 crore in the quarter ended December 2025 as against Rs 676.23 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales544.55676.23 -19 OPM %17.5135.10 - PBDT92.40248.13 -63 PBT45.46204.57 -78 NP36.72153.07 -76 Powered by Capital Market - Live News

 Cohance Lifesciences announced that the US FDA conducted an inspection at the Company`s Finished Dosage Formulations manufacturing facility (FDF Unit-I) located at Nacharam, Hyderabad, from 04 August 2025 to 12 August 2025. Following the inspection, a Form FDA-483 containing six observations was issued by the US FDA. Based on these observations, the USFDA classified the facility as �Official Action Indicated (OAI)� and subsequently issued a Warning Letter for the said facility. The Company is required to respond to the Warning Letter within the stipulated timelines prescribed by the US FDA and continues to engage with the regulator thereafter. The US revenues from this facility contributed less than 2% of consolidated revenues in FY25, with related EBITDA contribution below 1%. Powered by Capital Market - Live News

Pursuant to the USFDA inspection, Cohance Lifesciences has received a warning letter for the company`s Nacharam formulation facility. The Company had earlier informed the Stock Exchanges that the facility was classified as Official Action Indicated (OAI), and the said Warning Letter is in continuation of the same.The inspection was conducted by the USFDA from 04 August 2025 to 12 August 2025. Powered by Capital Market - Live News

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live News

Net profit of Cohance Lifesciences declined 46.50% to Rs 74.08 crore in the quarter ended September 2025 as against Rs 138.47 crore during the previous quarter ended September 2024. Sales declined 7.98% to Rs 555.57 crore in the quarter ended September 2025 as against Rs 603.77 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales555.57603.77 -8 OPM %21.7734.01 - PBDT127.79211.95 -40 PBT83.77174.16 -52 NP74.08138.47 -47 Powered by Capital Market - Live News